Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00165477 · ClinicalTrials.gov registry record · Phase 2
Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase 2 study of Glioblastoma and Gliosarcoma, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 4
- Study locations
NCT00165477 is a Phase 2 study of Glioblastoma and Gliosarcoma that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 23 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (79% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT00165477, a Phase 2 study of Glioblastoma and Gliosarcoma, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 4
- Study locations
Study Summary
\- The purpose of this study is to find out if the combination of lenalidomide and radiation therapy is effective in controlling tumor growth in patients with newly-diagnosed supratentorial glioblastoma or gliosarcoma.
Conditions Studied
Interventions
- RADIATION Radiation
- DRUG lenalidomide
Study Locations (4)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2005-09 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00165477
The ClinicalTrials.gov registry entry for NCT00165477 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (79% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Radiation is the first listed.
NCT00165477 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Virginia.
Frequently Asked Questions
What is clinical trial NCT00165477 about?
NCT00165477 is a clinical study titled "Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme". \- The purpose of this study is to find out if the combination of lenalidomide and radiation therapy is effective in controlling tumor growth in patients with newly-diagnosed supratentorial glioblastoma or gliosarcoma.
What is the current status of trial NCT00165477?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2005-09. Estimated completion is 2009-07.
What conditions does trial NCT00165477 study?
This clinical trial studies the following conditions: Glioblastoma, Gliosarcoma, Malignant Gliomas.
What interventions are being tested in trial NCT00165477?
The interventions under investigation include: Radiation (RADIATION), lenalidomide (DRUG).
Who is sponsoring clinical trial NCT00165477?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00165477 being conducted?
This trial has 4 study locations across Massachusetts, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.